On Friday July 9, 2021, the Union for Affordable Cancer Treatment (UACT) and Knowledge Ecology International (KEI) filed joint comments with the National Institutes of Health (NIH) regarding a prospective exclusive license for a cancer therapy technology. The Federal Register notice titled, “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific CD22 Chimeric Antigen Receptor (CAR) Therapies for the Treatment of B-Cell Malignancies” (86 FR 33326), outlined that the technology is to be licensed to Syncopation Life Sciences Inc. (Syncopation), which is based in Palo Alto, CA. The technology is an anti-CD22 CAR therapy, which has been shown to be effective inRead More →

The National Institute of Standards and Technology (NIST), a part of the US Department of Commerce, proposed a slate of detrimental changes to regulations in the Bayh-Dole Act governing “Rights to Federally Funded Inventions and Licensing of Government Owned Invention.” The public was given the opportunity to comment on the proposed changes, and by the close of the comment period on April 5, 2021 NIST had received over 81,000 comments on the issue. The proposed changes cover a variety of areas that impact policies concerning access to medicines and drug pricing, including patients’ rights to challenge the government’s grant of a taxpayer-funded invention to aRead More →

As COVID-19 continues to spread across the world, cancer patients, their doctors and families are struggling to find more information about how COVID-19 could affect them. From what is currently reported, cancer patients are a highly vulnerable group but we do not know yet how vulnerable. We know that cancer and cancer treatments can weaken a patient’s immune systems but there are not many data points, nor test results yet. What is most needed today is collaboration and openness. UACT signed this Open Letter to the World Health Organization (WHO) and its Member States on the proposal by Costa Rica to create a global poolRead More →

The Hill (TheHill.com) is an American political news website, based in Washington, D.C. which focuses on politics, policy, business and international relations. The Hill’s coverage includes the U.S. Congress, the presidency, and election campaigns. On its website, The Hill is described as standing “alone in delivering solid, nonpartisan reporting on the inner workings of Congress and the nexus of politics and business. The newspaper and its online platform connect the political players, define the issues, and influence the way Washington’s decision-makers view the debate.” On October 9, 2019, The Hill published an article by Peter Sullivan titled “2020 Democrats embrace aggressive step on drug prices.”Read More →

The British Labour Party’s platform on access to health, “MEDICINES FOR THE MANY: Public Health before Private Profit,” is organized in five well-written and powerful policy chapters. In 52 pages, the Labour Party takes a strong stand defending patients instead of profits. It also provides a clear explanation of a new set of needed health policies, fully laying out rationale to implementation. The first chapter covers the current United Kingdom (UK) health system including the pricing of medicines. The second chapter deals with the many problems that plague the existing health care system from the lack of transparency to the pharmaceutical lobby. The third chapter,Read More →